Background The synergy between the human immunodeficiency virus (HIV) and
Mycobacterium tuberculosis during co-infection of a host is well known. While this synergy is …

The HIV/AIDS (human immunodeficiency virus/acquired immunodeficiency syndrome) and
tuberculosis (TB) pandemics are perpetuated by a significant global burden of HIV/TB co …

Metabolic abnormalities are common in patients with human immunodeficiency virus (HIV)
infection and range from protein catabolism to lipodystrophy and dyslipidemia associated …

Imbalances in gut bacteria have been associated with multiple diseases. However, whether
there are disease-specific changes in gut microbial metabolism remains unknown. Here, we …

The HIV-human metabolic relationship is a complex interaction convoluted even more by
antiretroviral therapy (cART) and comorbidities. The ability of cART to undo the HIV induced …

HIV-1 infection leads to a depletion of CD4 T-cells associated with a persistent immune
inflammation and changes in cellular metabolism. Most effort of managing HIV infection with …

Both human immunodeficiency virus (HIV) and hepatitis C virus (HCV) may induce
metabolic disorders and cause liver complications. Therefore, we aim to analyze the …

With the advances in antiretroviral therapy (ART), HIV infection has been transformed into a
chronic medical condition that can be effectively managed like diabetes or hypertension. For …

Human Immunodeficiency Virus Type 1 (HIV-1) presents significant challenges to the
immune system, predominantly characterized by CD4+ T cell depletion, leading to Acquired …

Background Chronic metabolic changes relevant to human immunodeficiency virus type 1
(HIV-1) infection and in response to antiretroviral therapy (ART) remain undetermined …